| Back |
|
| Cross every hurdle |
| Product Name: |
| Tablets |
| Cefixime 100/200 mg |
| Overcomes widespread infection barrier |
| Respiratory Tract infections - Beta lactamase producing Haemophilus influenzae and M. catarrhalis strains are more susceptible to cefixime than to other oral cephalosporin (cephalexin, cefaclor, cefuroxime) |
| Bronchitis - Approved in the US for the treatment of acute Bronchitis. |
| Acute Otitis Media - More efficacious than amoxicillin in treating H. Influenza otitis media. |
| Urinary Tract infections - Suitable alternative to amoxycillin or cotrimoxazole in acute uncomplicated UTI |
| Enteric Fever - 100% susceptibility against resistant typhoid injection. |
| Gonorrhea - Compared with the intramuscular alternative, oral cefixime is painless to the patients, eliminates the psychologi effects associated with needle sticks in health care workers. |
| Post surgical Prophylaxis |
|
| Also available: CEFPAR-LB 200 DT (Cefixime 200 mg, Lactic Acid Bacillus 60 million spores)
|
|
| Gonorrhea
|
| RTI
|
| Acute otitis media
|
| UTI
|
| Bronchitis
|
|
Medical Jr.
| Scand J infect. Dis, Jan 1, 1993; 25(3): 373-378
|
| Am. J Ther, September 1, 1996; 3(9): 622-629
|
| J Pediatr. July 1, 1991; 19(1): 117-122
|
| Drugs, October 1, 1989; 38(4): 524-50
|
| New Microbio, Oct 2003; 26(4): 363-73
|
| Ann. Emerg. Med, March 1, 1996; 27(3): 299-304
|
|
| |
|
 |